Statement: The intervention section for the primary trial does not detail the type, dosage or duration of the intervention, unlike the secondary trial.
Primary_evidence: INTERVENTION 1:    Patients Undergoing Mastectomy Surgery   Number of individuals having mastectomy surgery who were approached for participation in the trial
Secondary_evidence: INTERVENTION 1:    Treatment (Tivantinib)   Patients receive tivantinib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection at baseline and periodically during study for c-Met expression, relevant markers (HGF and VEGF), PTEN loss, and PI3K mutation analysis by FISH and IHC. Archived tumor tissue samples are also analyzed.   Laboratory Biomarker Analysis: Correlative studies   Tivantinib: Given PO